<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>22380998</identifier>
<setSpec>2444-054X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Murillo-Lázaro, Cristina</dc:author>
<dc:author>Padilla-Valverde, David</dc:author>
<dc:author>Villarejo-Campos, Pedro</dc:author>
<dc:author>Martín-Fernández, Jesús</dc:author>
<dc:author>Menéndez-Sánchez, Pablo</dc:author>
<dc:description xml:lang="en">BACKGROUND Gliomatosis peritonei is the metastatic implantation of mature glial tissue within the peritoneal cavity of patients with ovarian teratomas. There is no clear guidance for how long these patients should be followed up. CLINICAL CASE We report the follow-up imaging findings of a 33-year-old female with abdominal distension and abdominal pain and who was postoperatively diagnosed with immature ovarian teratoma with gliomatosis peritonei. CONCLUSIONS Differentiation of peritoneal implants seems to be important for prognosis. Malignant transformations after several years cannot be excluded. Therefore, new studies will determine if it is necessary to create guidelines for the postsurgical monitoring of these patients.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>2011 May-Jun </dc:date>
<dc:title xml:lang="en">Gliomatosis peritonei: recurrence, treatment and surveillance.</dc:title>
<dc:publisher>Cirugia y cirujanos</dc:publisher>
</metadata>
</record>
</pubmed-document>
